Telix bets $1.7B on ITM to build radiopharma powerhouse
What's the deal? Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a merger valued at $1.65 billion upfront, with up to $700 million more tied to future milestones. The Australian-listed company will fold in ITM, a private German firm founded in 2004 and one of the world's largest suppliers of therapeutic radioisotopes.
The terms: The deal is structured on a cash-free, debt-free basis. After adjustments, ITM shareholders are expected to receive roughly $1.25 billion in Telix shares at $11.841 each, released as Nasdaq ADRs after escrow periods. The extra $700 million hinges on regulatory approvals and commercial sales of ITM-11.
Why now? Both companies operate in radiopharmaceuticals, which use radioactive isotopes to treat and diagnose disease. ITM is the only producer of globally scaled, commercial-grade lutetium-177 (177Lu), a key isotope for both approved and pipeline therapies.
What's the endgame? Telix wants to be a vertically integrated player controlling development, isotope production, and global manufacturing. ITM adds a distribution network across more than 65 countries and a late-stage candidate, ITM-11, for gastroenteropancreatic neuroendocrine tumours that has completed Phase 3 development.
By the numbers: ITM posted revenue of $273 million in 2025, growing at a 40% compound annual rate since 2021. Its profitable isotope business is set to deepen Telix's supply chain and contribute to cash generation.
What could go wrong? The transaction still needs Telix shareholder approval and other customary closing conditions. The bulk of the earn-out depends on ITM-11 clearing regulators and reaching the market.
The signal: The global nuclear medicine market is forecast to reach $41 billion by 2034, and demand for targeted radionuclide therapy is rising. Consolidation is following the money — securing scarce isotope supply is becoming as strategic as the drugs themselves.
Read more: listcorp.com
Image credit: U.S. Department of Energy
